Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This is a 2-arm, randomized, double-blind, placebo-controlled study aiming to determine the
efficacy and safety of DLBS1425 in combination with anthracyclin-based regimen as a
neoadjuvant therapy in subjects with previously untreated stage II or III (operable) breast
cancer.
The anthracyclin-based regimen in the study will be either CAF/iv and CEF/iv only. The
neoadjuvant anthracyclin-based chemotherapy will be given for 3 cycles. The length of each
cycle will be 21-28 days.